The cancers on which the high expression of FAP corresponded to high HR and low median survival were Bladder urothelial carcinoma (BLCA) (HR: 1.58), BRCA (HR: 1.69), Cervical squamous cell carcinoma (CESC) (HR: 1.81), ESCC (HR: 1.81), HNSC (HR: 1.61), KIRC (HR: 1.62), Kidney renal papillary cell carcinoma (KIRP) (HR: 3.82), Liver hepatocellular carcinoma (LIHC) (HR: 1.56), LUAD (HR: 1.36), Ovarian serous cystadenocarcinoma (OV) (HR: 1.27), Pancreatic ductal adenocarcinoma (PDAC) (HR: 1.5) and STAD (HR: 1.69) (Fig. 2c). This evidence concerns the gene FAP and cancer.